Should we treat acute hepatitis C? A decision and cost-effectiveness analysis

Hepatology

Volumn 67, Issue 3, 2018, Pages 837-846

  Bethea, Emily D ^a,b   Chen, Qiushi ^a,b   Hur, Chin ^a,b   Chung, Raymond T ^a,b   Chhatwal, Jagpreet ^a,b  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

^b HARVARD MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

LEDIPASVIR PLUS SOFOSBUVIR; VIRUS RNA; ANTIVIRUS AGENT;

ACUTE HEPATITIS C; ADULT; ANTIVIRAL THERAPY; ARTICLE; CHRONIC HEPATITIS C; COHORT ANALYSIS; CONTROLLED STUDY; COST CONTROL; COST EFFECTIVENESS ANALYSIS; DISEASE COURSE; FEMALE; FOLLOW UP; HUMAN; LIVER TRANSPLANTATION; MAJOR CLINICAL STUDY; MALE; MEDICAL HISTORY; PRIORITY JOURNAL; QUALITY ADJUSTED LIFE YEAR; SUSTAINED VIROLOGIC RESPONSE; TREATMENT DURATION; ACUTE DISEASE; CHRONIC DISEASE; COST BENEFIT ANALYSIS; DECISION MAKING; ECONOMICS; HEALTH CARE COST; HEPATITIS C; QUALITY OF LIFE; STATISTICS AND NUMERICAL DATA; THEORETICAL MODEL; TREATMENT OUTCOME; UNITED STATES;

ACUTE DISEASE; ADULT; ANTIVIRAL AGENTS; CHRONIC DISEASE; COST-BENEFIT ANALYSIS; DECISION MAKING; FEMALE; HEALTH CARE COSTS; HEPATITIS C; HUMANS; MALE; MODELS, THEORETICAL; QUALITY OF LIFE; QUALITY-ADJUSTED LIFE YEARS; TREATMENT OUTCOME; UNITED STATES;

EID: 85040867381     PISSN: 02709139     EISSN: 15273350     Source Type: Journal    
DOI: 10.1002/hep.29611     Document Type: Article

References (50)

1. Lavanchy D. The global burden of hepatitis C. Liver Int 2009;29(Suppl 1):74-81.
2. Mohd Hanafiah K, Groeger J, Flaxman AD, Wiersma ST. Global epidemiology of hepatitis C virus infection: new estimates of age-specific antibody to HCV seroprevalence. Hepatology 2013;57:1333-1342.
3. Collaborators TPOH. Global prevalence and genotype distribution of hepatitis C virus infection in 2015: a modelling study. Lancet Gastroenterol Hepatol 2017;2:161-176.
4. Grebely J, Page K, Sacks-Davis R, van der Loeff MS, Rice TM, Bruneau J, et al. The effects of female sex, viral genotype, and IL28B genotype on spontaneous clearance of acute hepatitis C virus infection. Hepatology 2014;59:109-120.
5. Hagan H, Pouget ER, Des Jarlais DC, Lelutiu-Weinberger C. Meta-regression of hepatitis C virus infection in relation to time since onset of illicit drug injection: the influence of time and place. Am J Epidemiol 2008;168:1099-1109.
6. Page K, Hahn JA, Evans J, Shiboski S, Lum P, Delwart E, et al. Acute hepatitis C virus infection in young adult injection drug users: a prospective study of incident infection, resolution, and reinfection. J Infect Dis 2009;200:1216-1226.
7. Mehta SH, Astemborski J, Kirk GD, Strathdee SA, Nelson KE, Vlahov D, Thomas DL. Changes in blood-borne infection risk among injection drug users. J Infect Dis 2011;203:587-594.
8. CDC. New Hepatitis C Infections Nearly Tripled Over Five Years. Atlanta, GA: CDC; 2017.
9. WHO. WHO: Guidelines for the Screening Care and Treatment of Persons with Chronic Hepatitis C Infection: Updated Version. In: Guidelines for the Screening Care and Treatment of Persons with Chronic Hepatitis C Infection: Updated Version. Geneva, Switzerland: WHO; 2016.
10. European Association for Study of Liver. EASL Recommendations on Treatment of Hepatitis C 2015. J Hepatol 2015;63:199-236.
11. AASLD. Hepatitis C guidance: AASLD-IDSA recommendations for testing, managing, and treating adults infected with hepatitis C virus. Hepatology 2017;62:932-954.
12. Hullegie SJ, Arends JE, Rijnders BJ, Irving WL, Salmon D, Prins M, et al. Current knowledge and future perspectives on acute hepatitis C infection. Clin Microbiol Infect 2015;21:797.e9-797.e17.
13. Deterding K, Spinner CD, Schott E, Welzel TM, Gerken G, Klinker H, et al. Ledipasvir plus sofosbuvir fixed-dose combination for 6 weeks in patients with acute hepatitis C virus genotype 1 monoinfection (HepNet Acute HCV IV): an open-label, single-arm, phase 2 study. Lancet Infect Dis 2017;17:215-222.
14. Basu RP, Shah NJ, Farbat S, John N, Kavali L, Shehi E, et al. Sofosbuvir and Ledipasvir versus Sofosbuvir and Simeprevir combination therapy in the management of acute hepatitis C: A randomized open label prospective clinical pilot study. SLAM C study. Interim data. Hepatology 2015;62(Suppl 1):736A.
15. Martin NK, Hickman M, Hutchinson SJ, Goldberg DJ, Vickerman P. Combination interventions to prevent HCV transmission among people who inject drugs: modeling the impact of antiviral treatment, needle and syringe programs, and opiate substitution therapy. Clin Infect Dis 2013;57(Suppl 2):S39-S45.
16. Wedemeyer H, Duberg AS, Buti M, Rosenberg WM, Frankova S, Esmat G, et al. Strategies to manage hepatitis C virus (HCV) disease burden. J Viral Hepat 2014;21(Suppl 1):60-89.
17. Micallef JM, Kaldor JM, Dore GJ. Spontaneous viral clearance following acute hepatitis C infection: a systematic review of longitudinal studies. J Viral Hepat 2006;13:34-41.
18. Chhatwal J, Kanwal F, Roberts MS, Dunn MA. Cost-effectiveness and budget impact of hepatitis C virus treatment with sofosbuvir and ledipasvir in the United States. Ann Intern Med 2015;162:397-406.
19. Afdhal N, Zeuzem S, Kwo P, Chojkier M, Gitlin N, Puoti M, et al. Ledipasvir and sofosbuvir for untreated HCV genotype 1 infection. N Engl J Med 2014;370:1889-1898.
20. Kamal SM. Acute hepatitis C: a systematic review. Am J Gastroenterol 2008;103:1283-1297; quiz, 1298.
21. Liu S, Cipriano LE, Holodniy M, Goldhaber-Fiebert JD. Cost-effectiveness analysis of risk-factor guided and birth-cohort screening for chronic hepatitis C infection in the United States. PLoS One 2013;8:e58975.
22. Armstrong GL, Wasley A, Simard EP, McQuillan GM, Kuhnert WL, Alter MJ. The prevalence of hepatitis C virus infection in the United States, 1999 through 2002. Ann Intern Med 2006;144:705-714.
23. Arias E. United States life tables, 2007. National vital statistics reports; vol 59 no 9. Hyattsville, MD: National Center for Health Statistics. 2011.
24. Thein H, Yi Q, Dore G, Krahn M. Estimation of stage specific fibrosis progression rates in chronic hepatitis C virus infection: A meta analysis and meta regression. Hepatology 2008;48:418-431.
25. Fattovich G, Giustina G, Degos F, Tremolada F, Diodati G, Almasio P, et al. Morbidity and mortality in compensated cirrhosis type C: a retrospective follow-up study of 384 patients. Gastroenterology 1997;112:463-472.
26. Planas R, Ballesté B, Antonio Álvarez M, Rivera M, Montoliu S, Anton Galeras J, et al. Natural history of decompensated hepatitis C virus-related cirrhosis. A study of 200 patients. J Hepatol 2004;40:823-830.
27. Lang K, Danchenko N, Gondek K, Shah S, Thompson D. The burden of illness associated with hepatocellular carcinoma in the United States. J Hepatol 2009;50:89-99.
28. Wolfe R, Roys E, Merion R. Trends in organ donation and transplantation in the United States, 1999-2008. Am J Transplant 2010;10:961-972.
29. Thuluvath P, Guidinger M, Fung J, Johnson L, Rayhill S, Pelletier S. Liver transplantation in the United States, 1999-2008. Am J Transplant 2010;10:1003-1019.
30. Chhatwal J, Ferrante SA, Brass C, El Khoury AC, Burroughs M, Bacon B, et al. Cost-Effectiveness of boceprevir in patients previously treated for chronic hepatitis C genotype 1 Infection in the United States. Value in Health 2013;16:973-986.
31. First Databank. Drug Pricing Policy. South San Francisco, CA: First Databank; 2014. Accessed at www.firstdatabank.com/Support/drug-pricing-policy.aspx on 6 March 2014.
32. He T, Li K, Roberts MS, Spaulding AC, Ayer T, Grefenstette JJ, Chhatwal J. Prevention of Hepatitis C by Screening and Treatment in U.S. Prisons. Ann Intern Med 2016;164:84-92.
33. McAdam-Marx C, McGarry LJ, Hane CA, Biskupiak J, Deniz B, Brixner DI. All-cause and incremental per patient per year cost associated with chronic hepatitis C virus and associated liver complications in the United States: a managed care perspective. J Manag Care Pharm 2011;17:531-546.
34. The Bureau of Labor Statistics. Consumer Price Index—All Urban Consumers. Washington, DC: U.S. Department of Labor; 2017.
35. Chong CA, Gulamhussein A, Heathcote EJ, Lilly L, Sherman M, Naglie G, Krahn M. Health-state utilities and quality of life in hepatitis C patients. Am J Gastroenterol 2003;98:630-638.
36. Hanmer J, Lawrence WF, Anderson JP, Kaplan RM, Fryback DG. Report of nationally representative values for the noninstitutionalized US adult population for 7 health-related quality-of-life scores. Med Decis Making 2006;26:391-400.
37. Hellard ME, Jenkinson R, Higgs P, Stoove MA, Sacks-Davis R, Gold J, et al. Modelling antiviral treatment to prevent hepatitis C infection among people who inject drugs in Victoria, Australia. Med J Aust 2012;196:638-641.
38. Elbasha EH. Model for hepatitis C virus transmissions. Math Biosci Eng 2013;10:1045-1065.
39. Vickerman P, Hickman M, Judd A. Modelling the impact on Hepatitis C transmission of reducing syringe sharing: London case study. Int J Epidemiol 2007;36:396-405.
40. Enns EA, Zaric GS, Strike CJ, Jairam JA, Kolla G, Bayoumi AM. Potential cost-effectiveness of supervised injection facilities in Toronto and Ottawa, Canada. Addiction 2016;111:475-489.
41. Irwin A, Jozaghi E, Bluthenthal RN, Kral AH. A cost-benefit analysis of a potential supervised injection facility in San Francisco, California, USA. J Drug Issues 2017;47:164-184.
42. Bayoumi AM, Zaric GS. The cost-effectiveness of Vancouver's supervised injection facility. CMAJ 2008;179:1143-1151.
43. Kwon JA, Anderson J, Kerr CC, Thein HH, Zhang L, Iversen J, et al. Estimating the cost-effectiveness of needle-syringe programs in Australia. AIDS 2012;26:2201-2210.
44. AASLD. Guidelines: Initial Treatment of HCV Infection. In: Update; 2017.
45. AASLD-IDSA. Recommendations for testing, managing, and treating hepatitis C. http://www.hcvguidelines.org. [Accessed 09/10/2017].
46. World Health Organization. Combating hepatitis B and C to reach elimination by 2030. Geneva, Switzerland: World Health Organization. 2016.
47. CDC. Viral Hepatitis—Statistics & Surveillance. Atlanta, GA: Centers for Disease Control and Prevention. 2015.
48. Zibbell JE, Iqbal K, Patel RC, Suryaprasad A, Sanders KJ, Moore-Moravian L, et al. Increases in hepatitis C virus infection related to injection drug use among persons aged
49. Buckley GJ, Strom BL, eds. Eliminating the Public Health Problem of Hepatitis B and C in the United States: Phase One Report. National Academies Press, Washington (DC); 2016.
50. Grebely J, Bruggmann P, Treloar C, Byrne J, Rhodes T, Dore GJ. Expanding access to prevention, care and treatment for hepatitis C virus infection among people who inject drugs. Int J Drug Policy 2015;26:893-898.